Despite the exponential growth in the literature on modelling and simulation studies of impact and cost-effectiveness in different aspects of healthcare, there is no clear consensus on the appropriate role of modelling in the development of recommendations in clinical guidelines. This is compounded both ...
During 9–12 March 2014, WHO convened a meeting of the Guideline Development Group (GDG) comprising 52 individuals representing a wide range of stakeholders, for the purpose of reviewing, and where appropriate, revising its Medical eligibility criteria for contraceptive use, fourth edition (MEC) guidanc...
In this second supplement (December 2014) to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, recommendations from two guideline development processes are included: post-exposure prophylaxis for HIV; the use of co-trimoxazole prophylaxis for H...
Determinar cuál es el mejor algoritmo de diagnóstico en adolescentes y adultos, con infección por VIH/Sida.
Establecer qué valoraciones clÃnicas y de laboratorio debe incluir la valoración inicial del paciente con diagnóstico de VIH/Sida. Determinar cuál debe ser el tiempo oportuno para el inicio...
Górriz, J. L;
Gutiérrez, F;
Trullas, J. C;
Arazo, P;
Arribas, J. R;
Barril, G;
Cervero, M;
Cofan, F;
Domingo, P;
Estrada, V;
Fulladosa, X;
Galindo, M. J;
Gracia, S;
Iribarren, J. A;
Knobel, H;
López-Aldeguer, J;
Lozano, F;
MartÃnez-Castelao, A;
MartÃnez, E;
Mazuecos, M. A;
Miralles, C;
Montañés, R;
Negredo, E;
Palacios, R;
Pérez-ElÃas, M. J;
Portilla, J;
Praga, M;
Quereda, C;
Rivero, A;
SantamarÃa, J. M;
Sanz, J;
Miró, J. M.
OBJETIVO: Actualizar las recomendaciones sobre la evaluación y el manejo de la afectación renal en pacientes con infección por el virus de la inmunodeficiencia humana (VIH). MÉTODOS: Este documento ha sido consensuado por un panel de expertos del Grupo de Estudio de Sida (GESIDA) de la Sociedad EspaÃ...
GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years.
Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question...
These consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and treatme...
This guideline provides an evidence-based recommendation on the use of adult male circumcision devices for HIV prevention in public health programmes in high HIV prevalence, resource-limited settings. It also presents key programmatic considerations for the introduction and use of these devices in public...
Adolescents (10–19 years) and young people (20–24 years) continue to be vulnerable, both socially and economically, to HIV infection despite efforts to date. This is particularly true for adolescents — especially girls — who live in settings with a generalized HIV epidemic or who are members of k...
